Federated Hermes Inc. Takes Position in Qiagen N.V. (NYSE:QGEN)

Federated Hermes Inc. purchased a new stake in shares of Qiagen N.V. (NYSE:QGEN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,739 shares of the company’s stock, valued at approximately $150,000.

Other large investors have also made changes to their positions in the company. LPL Financial LLC lifted its stake in Qiagen by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company’s stock valued at $768,000 after buying an additional 432 shares during the period. Geode Capital Management LLC lifted its stake in Qiagen by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,075,184 shares of the company’s stock valued at $47,878,000 after buying an additional 19,513 shares during the period. Wells Fargo & Company MN lifted its stake in Qiagen by 31.8% in the fourth quarter. Wells Fargo & Company MN now owns 66,779 shares of the company’s stock valued at $2,974,000 after buying an additional 16,106 shares during the period. Cerity Partners LLC lifted its stake in Qiagen by 26.0% in the fourth quarter. Cerity Partners LLC now owns 18,143 shares of the company’s stock valued at $814,000 after buying an additional 3,749 shares during the period. Finally, Capital Fund Management S.A. acquired a new position in Qiagen in the fourth quarter valued at about $4,664,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Down 0.7%

NYSE:QGEN opened at $48.02 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a 50-day simple moving average of $48.02 and a 200 day simple moving average of $43.54. The company has a market cap of $10.67 billion, a PE ratio of 28.37, a PEG ratio of 2.45 and a beta of 0.64. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%. The business’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company earned $0.55 earnings per share. On average, sell-side analysts expect that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen’s dividend payout ratio (DPR) is currently 14.79%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on QGEN shares. Wall Street Zen lowered Qiagen from a “strong-buy” rating to a “buy” rating in a research note on Monday. Bank of America increased their target price on Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, June 26th. Robert W. Baird raised their price target on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Thursday. Finally, Barclays started coverage on Qiagen in a research report on Tuesday, June 24th. They set an “overweight” rating and a $55.00 price target on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.